Project: Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as drugs against tuberculosis
- project duration
- 01-SEP-02 – 31-AUG-05
- Compared to humans most bacteria use a different biosynthetic route for the production of isoprenoids: the 1-deoxy-D-xylulose 5-phosphate (DOXP) pathway. The antibiotic fosmidomycin represents a potent inhibitor of DOXP reductoisomerase (Dxr), an enzyme involved in the DOXP-pathway. However, it needs to be further developed to encompass the physicochemical requirements of an ideal antimycobacterial drug. The primary goal of this multidisciplinary project is the rational design of improved Dxr inhibitors Dxr inhibitors as anti-TB drugs.